Preferences of hxealthy men for two different endocrine treatment options offered for locally advanced prostate cancer

References

• Cancer Research UK. Scientific Yearbook; 2004
   Google Scholar
• Feldman-Stewart D, Brundage MD, Hayter C, et al. What prostate cancer patients should know: variation in professionals’ opinions. Radiother Oncol 1998;49:111–23
   Google Scholar
• Davison BJ, Parker PA, Goldenberg SL. Patients’ preferences for communicating a prostate cancer diagnosis and participating in medical decision-making. Br J Urol Int 2004;93:47–51
   Google Scholar
• Templeton H, Coates V. Informational needs of men with prostate cancer on hormonal manipulation therapy. Patient Educ Couns 2003;49:243–56
   PubMed Web of Science ®Google Scholar
• Boccardo F, Barichello M, Battaglia M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 2002;42:481–90
   PubMed Web of Science ®Google Scholar
• Carroll PR, Kantoff PW, Balk SP, et al. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002;60(3 Suppl 1):1–6
   Google Scholar
• Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000;164:1579–82
   PubMed Web of Science ®Google Scholar
• Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median follow-up of 5.4 years. J Urol 2004;172:1865–70
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999;17:2027–38
   PubMed Web of Science ®Google Scholar
• Scholz M, Lamb R. Antiandrogen monotherapy. Available from: www.prostateoncology.com; 2004 [last accessed February 2005]
   Google Scholar
• Migliari R, Muscas G, Usai E. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer. J Urol 1992;148:338–41
   Google Scholar
• Iversen P, Tammela TL, Vaage S, et al. A randomised comparison of bicalutamide (‘Casodex’) 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early nonmetastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Urol 2002;42:204–11
   Google Scholar
• Tyrrell CJ, Payne H, Tammela TL, et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 2004;60: 476–83
   PubMed Web of Science ®Google Scholar
• Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004;22:2546–53
   PubMed Web of Science ®Google Scholar
• Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181–6
   PubMed Web of Science ®Google Scholar
• Basaria S, Lieb 2nd J, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002;56:779–86
   Google Scholar
• Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. New Engl J Med 2005;352:154–64
   PubMed Web of Science ®Google Scholar
• Iversen P. Bicalutamide monotherapy for early stage prostate cancer: an update. J Urol 2003;170:S48–52 [discussion S52–4]
   Google Scholar
• Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M. Patients’ preferences for the management of non-metastatic prostate cancer: discrete choice experiment. Br Med J 2004;328: 382
   Google Scholar
• Fallowfield LJ, Hall A, Maguire P, Baum M, A’Hern RP. Psychological effects of being offered choice of surgery for breast cancer. Br Med J 1994;309:448
   Google Scholar
• Fallowfield L, McGurk R, Dixon M. Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. Eur J Cancer 2004;40:2403–10
   Google Scholar
• Feldman-Stewart D, Brundage MD, Nickel JC, MacKillop WJ. The information required by patients with early-stage prostate cancer in choosing their treatment. Br J Urol Int 2001;87: 218–23
   Google Scholar
• Jonker-Pool G, Hoekstra HJ, van Imhoff GW, et al. Male sexuality after cancer treatment – needs for information and support: testicular cancer compared to malignant lymphoma. Patient Educ Couns 2004;52:143–50
   Google Scholar
• Detmar SB, Aaronson NK, Wever LD, Muller M, Schornagel JH. How are you feeling? Who wants to know? Patients’ and oncologists’ preferences for discussing health-related quality-of-life issues. J Clin Oncol 2000;18:3295–301
   Google Scholar
• Fallowfield L, Jenkins V. Effective communication skills are the key to good cancer care. Eur J Cancer 1999;35:1592–7
   PubMed Web of Science ®Google Scholar
• Metz R, Namer M, Adenis L, et al. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial. Am J Clin Oncol 1988;11(Suppl 2):S112–4
   Google Scholar
• Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001;19:72–80
   Google Scholar
• Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999;54:607–11
   PubMed Web of Science ®Google Scholar